Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 191

Sort by

Sort Order Select

Journal Articles

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Erin W. Meermeier, Kirsten Pfeffer, Caleb K. Stein, Meaghen E. Sharik, Megan T. Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (25): 3072–3085.

https://doi.org/10.1182/blood.2025029215

Published: 2025

Includes: Supplemental data

Journal Articles

Reprogramming glutamine metabolism enhances BCMA -CAR T-cell fitness and therapeutic efficacy in multiple myeloma

Blood (2025) 146 (24): 2931–2944.

https://doi.org/10.1182/blood.2024027496

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5772.

https://doi.org/10.1182/blood-2025-5772

Published: 2025

Journal Articles

Retention of immunosuppressive C1Q macrophages following therapeutic interventions imparts negative outcomes across human multiple myeloma studies

Caleb Stein, Erin Meermeier, Taxiarchis Kourelis, Joselle Cook, Yuliza Shotts, Yuan Zhu, Chang-Xin Shi, Kirsten Pfeffer, Meaghen Sharik, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 7481.

https://doi.org/10.1182/blood-2025-7481

Published: 2025

Journal Articles

Remodeling the bone marrow tumor microenvironment with CART cell therapy to overcome resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2025-1028

Published: 2025

Journal Articles

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Blood (2025) 146 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2025-3939

Published: 2025

Journal Articles

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Julius Michel, Jan Frenking, Anna Metzler, Erin Meermeier, Antonia Schach, Vera Thiel, Tim Wagner, Niklas Kehl, Stefanie Huhn, Alexander Brobeil, Carsten Müller-Tidow, P. Leif Bergsagel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Marta Chesi, Marc Raab, Niels Weinhold, Mirco Friedrich

Blood (2025) 146 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2025-3951

Published: 2025

Journal Articles

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Lorenzo Lindo, Kevin Hay, Erin Meermeier, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2025-5728

Published: 2025

Journal Articles

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2025-2139

Published: 2025

Journal Articles

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Yusuke Yamashita, Jonathan Patton, Yuliza Shotts, Megan Du, Meaghen Sharik, Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Caleb Stein, Erin Meermeier, Marta Chesi, Lanbo Xiao, Arul Chinnaiyan, Benjamin Barwick, P. Leif Bergsagel

Blood (2025) 146 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2025-2138

Published: 2025

Journal Articles

Myc super-enhancer dynamics in T-ALL

Georgios Tousinas, Vasili Toliopoulos, Melissa Tracy, Akinola Olumide Emmanuel, Khashayarsha Khazaie, Thomais Papamarcaki, P. Leif Bergsagel, Fotini Gounari

Blood (2025) 146 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2025-5030

Published: 2025

Journal Articles

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Blood (2025) 146 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2025-4585

Published: 2025

Journal Articles

Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma

Kevin Shim, Mariano Arribas, Fabio Samir Vargas Cely, Udit Yadav, J Wiedmeier-Nutor, Nathan Punwani, Gabriela Alatorre, Sharene Best, Katalin Kelemen, Saurabh Chhabra, P. Leif Bergsagel, David Murray, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2025-2201

Published: 2025

Journal Articles

Alternate dosing schedules of BCMA-directed T cell engagers display altered pathways of relapse in syngeneic vk*MYC multiple myeloma

Erin Meermeier, Caleb Stein, Meaghen Sharik, Megan Du, Yuan Zhu, Chang-Xin Shi, Kirsten Pfeffer, Keith Abayasiriwardana, Timothy Fisher, Kristin Bompiani-Myers, P. Leif Bergsagel, Marta Chesi

Blood (2025) 146 (Supplement 1): 913.

https://doi.org/10.1182/blood-2025-913

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

J Wiedmeier-Nutor, Mariano Arribas, Karl Franke, Juana Figueroa Aguirre, Katalin Kelemen, Udit Yadav, P. Leif Bergsagel, Saurabh Chhabra, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2025-4020

Published: 2025

Journal Articles

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Blood (2025) 146 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2025-5953

Published: 2025

Journal Articles

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

J Erin Wiedmeier-Nutor, Surendra Dasari, Richard Kumaran Kandasamy, Kiran Manalaparthi, Laura Ann Bruins, Gregory Ahmann, Mariano Arribas, P. Leif Bergsagel, Akhilesh Pandey, Esteban Braggio, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2024-206239

Published: 2024

Journal Articles

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Blood (2024) 144 (Supplement 1): 671.

https://doi.org/10.1182/blood-2024-202224

Published: 2024

Journal Articles

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Debashree Basudhar, Dante Descalzi-Montoya, Hao Tang, Minshi Wang, Fan Wu, P. Leif Bergsagel, Xavier Leleu, Daniela Hosseyni, Maria Chaudhry, Nathan Martin, Ethan G. Thompson

Blood (2024) 144 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2024-198740

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Reprogramming glutamine metabolism enhances BCMA -CAR T-cell fitness and therapeutic efficacy in multiple myeloma

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Retention of immunosuppressive C1Q macrophages following therapeutic interventions imparts negative outcomes across human multiple myeloma studies

Remodeling the bone marrow tumor microenvironment with CART cell therapy to overcome resistance in multiple myeloma

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Myc super-enhancer dynamics in T-ALL

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma

Alternate dosing schedules of BCMA-directed T cell engagers display altered pathways of relapse in syngeneic vk*MYC multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only